The new implant’s hybrid design was crafted to boost patient recovery and procedural efficacy. Credit: Sasin Tipchai/Pixabay.

Medinol has announced the first-in-human (FIH) implantation of the ChampioNIR drug-eluting peripheral stent system at Alfred Hospital in Melbourne, Australia.

This implantation demonstrated a new hybrid mechanical design aimed at enhancing patient outcomes and procedural success.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The ChampioNIR stent system represents a transformative technology in peripheral stenting. Its structure combines a metallic component for radial support and a bioresorbable polymeric mesh for longitudinal flexibility.

This design ensures durability and adaptability within challenging anatomical regions. Additionally, the stent features an advanced drug-elution method that allows for extended therapeutic dosing of a ‘limus’ drug across large peripheral vessels.

The implantation was performed by Dr Gerard Goh and Dr Thodur Vasudevan, who are part of the CHAMPIONSHIP first in human study.

See Also:

The Alfred Hospital interventional radiology head professor Gerard Goh said: “We were impressed with ChampioNIR’s deliverability and its straightforward deployment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The Frictionless Deployment Mechanism made the precise positioning of the stent very straightforward.”

This study aims to enrol 30 patients across seven sites in Australia and the US. The successful procedure in Melbourne is a promising start for this international clinical trial.

CHAMPIONSHIP study principal investigator professor Sahil Parikh said: “The ChampioNIR stent represents a breakthrough in treatment for SFA lesions.”

Medinol CEO Dr Yoram Richter said: “Medinol is excited to bring to clinical practice the culmination of years of research and development into novel stent designs, tailor-made for unmet clinical challenges in vascular interventions.”

Established in 1992, the company is engaged in the development of advanced solutions to improve the management of vascular diseases.

It has more than 300 employees and offices in the US and Israel.